

Subscription Offer



Capital increase until December 13, 2024, by a maximum of CHF 6,107,871 / 872,553 registered shares

Issuer	InnoMedica Holding AG, Zug
Existing shares	15,705,955 fully paid-in registered shares with a nominal value of CHF 0.10 each
Capital increase	Increase by a maximum of 872,553 fully paid-in newly issued shares nominal CHF 87,255.30 to a maximum of 16,578,508 shares nominal CHF 1,657,850.80
Issue price	CHF 7.00 per share
Denomination	Minimum 2,000 new shares at a price of CHF 7.00 each (total CHF 14,000). Shareholders who subscribe below the minimum by exercising their subscription rights and wish to have their shares delivered to their securities account will cover the resulting bank fees.
Subscription right	Preferential subscription rights of the existing shareholders (no trading of subscription rights planned)
Subscription deadline	Until Friday, December 13, 2024, by postal mail to InnoMedica Holding AG, Dr. Jonas Zeller, CFO, Gesellschaftsstrasse 16, 3001 Bern (copy by e-mail: ir@innomedica.com)
Deposit	Until Friday, December 13, 2024, for the subscription of new shares in the escrow account belonging to InnoMedica Holding AG, Kapitalerhöhung, 6300 Zug (UBS Switzerland AG, IBAN: CH22 0023 0230 8867 10D7 L).
Allocation	According to subscription rights. The allocation of unexercised subscription rights will be effected by the Board of InnoMedica Holding AG.
Tradeability	Freely tradable registered shares, OTC (SIX SIS ISIN: CH0558973902)
Securitization	Confirmation of receipt of payment by InnoMedica Holding AG, delivery of the shares after their inception in the share account of the buyer.
Jurisdiction	Seat of InnoMedica Holding AG: Zug, Switzerland.
Dividend	The shares are entitled to dividends for the full fiscal year 2024.
Risks	Persons interested in the offer receive the Offering Prospectus, the Business Information 2024 incl. update, as well as the Annual Report 2023 and the unaudited half-year financial statement 2024. The revised Consolidated Financial Statements 2023 according to IFRS will also be made available upon request. The undersigned is aware that he/she acquires the shares as a participation in the company with rights to a dividend. He/she cannot derive any rights from the submitted information to the subsequent performance (of the shares or the company).
Principal point of payment	UBS Switzerland AG, PWJ8-NT4, P.O. Box, 3001 Bern Phone: +41 (0)31 336 47 70, e-mail: norbert.mullis@ubs.com
Contact	Investor Relations, Phone +41 (0)44 383 88 22, e-mail: ir@innomedica.com

For this offer, a prospectus according to Art. 35 et seq of the Federal Act on Financial Services (FIDLEG) is issued, approved by SIX Exchange Regulation AG on November 15, 2024.

InnoMedica Holding AG

Gesellschaftsstrasse 16 | CH-3012 Bern | Phone: +41 (0)44 383 88 22 | info@innomedica.com | www.innomedica.com

Share Subscription Form

Capital Increase

Capital increase from CHF 1,570,595.50 to a maximum of CHF 1,657,850.80

The undersigned

Name First name

Address ZIP/City

Phone E-mail

Custody account for the share transfer

Bank Custody Account No.

Bank account for eventual backpayment

Bank IBAN

participates in the capital increase 2024 as follows, with regard to the decision of the extraordinary General Assembly 2024 to create a capital spread as well as the decision by the Board of Directors on November 12, 2024, to issue a maximum of 872,553 registered shares with a nominal value of CHF 0.10 for an issue price of CHF 7.00 per share, and the Offering Prospectus of InnoMedica Holding AG dated November 2024:

Subscription of new shares

at CHF 7.00 each

x CHF 7.00 =

Number of new shares Total subscription CHF

Deposit on the escrow account (UBS Switzerland AG)

IBAN: CH22 0023 0230 8867 10D7 L
Belonging to: InnoMedica Holding AG
Kapitalerhöhung, 6300 Zug
SWIFT: UBSWCHZH80A

The subscription is valid if until Friday, December 13, 2024,

- the signed form is transmitted by postal mail to the mailing address of InnoMedica (see below for details)
- the corresponding amount for the subscribed new shares is deposited in the escrow account of InnoMedica (see below for details)

Concurrent submissions by e-mail are welcome, but do not replace the mandatory postal submission.

The new shares are allocated in priority based on the subscription rights in possession of the undersigned and, additionally, based on the decision of the Board of Directors.

Current shareholders who would like to participate in the capital increase in accordance to or in excess of their subscription rights, must be entered accordingly in the share register with their shares or submit a bank statement of the shares in their securities account as of December 13, 2024 on the closing date. If existing shareholders use their subscription rights to subscribe for shares below the minimum number of shares, they must pay the transaction costs of CHF 64.86 to Swiss bank custody accounts (except UBS custody accounts exempt from transaction costs) and transfer the amount to the transaction account (IBAN: CH21 0023 5235 5668 5202 F in the name of InnoMedica Holding AG, 6300 Zug) by Friday, December 13, 2024.

Date Signature

Mailing address

InnoMedica Holding AG
Dr. Jonas Zeller, CFO
Gesellschaftsstrasse 16, P.O. Box 2553, 3001 Bern
Copy by e-mail to: ir@innomedica.com

InnoMedica Holding AG

Gesellschaftsstrasse 16 | CH-3012 Bern | Phone: +41 (0)44 383 88 22 | info@innomedica.com | www.innomedica.com